Myovant Sciences (NYSE:MYOV) announced its earnings results on Thursday. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.93) by ($0.06), Fidelity Earnings reports.
MYOV stock traded down $2.17 on Friday, reaching $19.12. 4,115 shares of the company traded hands, compared to its average volume of 60,154. Myovant Sciences has a one year low of $11.30 and a one year high of $27.45. The company has a quick ratio of 3.07, a current ratio of 3.07 and a debt-to-equity ratio of 0.73. The firm has a market cap of $1.56 billion, a PE ratio of -7.90 and a beta of 0.12.
Several research analysts have recently issued reports on MYOV shares. Zacks Investment Research raised Myovant Sciences from a “sell” rating to a “hold” rating in a research report on Wednesday, October 10th. Goldman Sachs Group started coverage on Myovant Sciences in a research report on Friday, October 26th. They issued a “neutral” rating and a $25.00 target price for the company. JPMorgan Chase & Co. started coverage on Myovant Sciences in a research report on Thursday, September 13th. They issued an “overweight” rating and a $39.00 target price for the company. Finally, Cowen reissued a “buy” rating on shares of Myovant Sciences in a research report on Friday. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Myovant Sciences currently has an average rating of “Buy” and a consensus price target of $29.20.
Myovant Sciences Company Profile
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.
Recommended Story: Return on Equity (ROE)
Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.